Rapamycin, NAD precursors, senolytics, epigenetic reprogramming.
Both nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) reliably raise blood NAD+ levels.
Longevity is the most over-marketed and under-evidenced category in adult health. The 2026 field still has no FDA-approved intervention that extends human lifespan, no validated biomarker that closes the gap between "the test moved" and "you lived longer," and a long list of compounds whose case rests entirely on rodent data. The seven articles cited below filter that noise. Each one is built around a specific molecule, a specific mechanism, and the actual human evidence — not the marketing deck.
The clearest signal in 2026 belongs to NAD+ precursors, with caveats. NMN and NR both reliably raise circulating NAD+. Whether that raises healthspan in humans remains the open question — the trials we have are short, small, and use surrogate endpoints (grip strength, walking speed, insulin sensitivity) that are not the same as "lived two years longer." The honest read is: probably real for muscle and metabolic markers in older adults, almost certainly oversold for everyone under 50.
Rapamycin remains the most interesting drug in the conversation and the one with the most consistent rodent lifespan data. Off-label human use is now common in longevity clinics, dosed weekly at 5–10 mg to preserve immune function. The PEARL trial is the closest thing to a real human study. It is also not powered for lifespan. Senolytics — dasatinib + quercetin, fisetin — are the same story: clean animal data, sparse human data, real interest from clinicians who actually run the labs.
Taurine deserves the placement it has after the 2023 Science paper, but the field has cooled slightly since: the human supplementation trials underway are still reading out and the mouse work has not replicated cleanly in every lab. Urolithin A has the strongest mitophagy story of any over-the-counter supplement and the cleanest 2025 immune-aging RCT — which is why it sits where it sits. Microbiome interventions, including the spore-formers and psychobiotics, are climbing — but mostly via metabolic and inflammatory endpoints, not lifespan.
Underneath all of it: VO2max remains the single best-replicated longevity variable we have. Every drug above is being measured against a question that running, lifting, and sleep already answer better. The pieces below explain where each compound actually fits.
Lactobacillus, Bifidobacterium, Akkermansia, spore-formers, and psychobiotics. What each does, what the evidence shows, and how to think about probiotic supplementation without falling for CFU (colony-forming unit) theater.
Urolithin A (UA) is not a drug. It is a gut-derived metabolite — what your microbiome makes from pomegranates, walnuts, and berries when the right bacteria are present.
A single paper in Science turned taurine — a molecule most people associate with energy drinks — into a serious longevity candidate overnight. Circulating levels drop 67% between childhood and age 60. Mouse lifespan extended 10–12%.
VO2max is the modifiable variable with the largest documented effect on all-cause mortality. The Cooper Institute data does not just show a correlation — it shows a hazard ratio comparable to or greater than smoking.
The animal data is real. The human trials are smaller, shorter, and far more equivocal than the cultural conversation reflects.
Life Biosciences' ER-100 — an adeno-associated virus delivering three Yamanaka factors under a doxycycline switch — became the first partial cellular reprogramming therapy authorized for human testing. Initial cohort: about a dozen p…
Three storylines will move this field hard in the next 12 months. The first is rapamycin's first proper human aging trial — the PEARL follow-on protocols are recruiting and any clean signal on immune function or biological-age clocks will shift the entire off-label landscape. The second is the TAME (Targeting Aging with Metformin) results, finally past their funding bottleneck and expected to read out across multiple secondary endpoints; if metformin moves the curve in non-diabetics, every other longevity compound gets a new comparator.
The third is the epigenetic-clock validity question. Horvath-style methylation clocks have been the field's de facto biomarker for almost a decade, but the gap between "the clock moved younger" and "the person lived longer" is still open — and Yamanaka-factor partial reprogramming work in primates will either close that gap or expose how much of the longevity-supplement industry is selling a methylation shift instead of a survival benefit. We are watching all three. Until they land, our advice doesn't change: train hard, sleep enough, eat real food, and treat every pill in this category as a bet, not a plan.